New treatments to target and eliminate specific types of tumors
Novel therapeutics for the targeted eradication of DDR-defective tumors
This study is exploring new treatments for patients with tough-to-treat tumors that lack a specific enzyme, aiming to use special compounds to safely destroy these cancer cells while protecting healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10893619 on NIH RePORTER |
What this research studies
This research focuses on developing novel therapeutics that specifically target tumors lacking the O6-Methylguanine methyltransferase (MGMT) enzyme, which are often resistant to standard treatments. By using new compounds called 2-fluoroethylating agents (FEtAs), the research aims to selectively eradicate these MGMT-deficient tumors while minimizing harm to healthy tissues. The approach involves inducing DNA damage in the cancer cells that cannot be repaired, leading to their death, while allowing normal cells to recover. This targeted strategy could improve treatment outcomes for patients with certain aggressive cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with MGMT-deficient tumors, such as certain types of glioblastomas, colon cancers, and small cell lung cancers.
Not a fit: Patients with tumors that express the MGMT enzyme or those with other types of cancers not targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with MGMT-deficient tumors, potentially improving survival rates.
How similar studies have performed: While the approach of targeting MGMT-deficient tumors is established, the specific use of 2-fluoroethylating agents represents a novel strategy that has not been extensively tested in clinical settings.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Herzon, Seth B. — Yale University
- Study coordinator: Herzon, Seth B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.